-- Improved sample quality, workflow efficiencies and
flexibility drive transition to Hologic platform
MANCHESTER, England,
April 8, 2015 /PRNewswire/ --
Hologic, Inc. (NASDAQ: HOLX) today announced that Luxembourg's National Health Laboratory, which
operates under the Ministry of Health, has successfully implemented
the Company's comprehensive product platform for its cervical
cancer screening programme. The conversion to Hologic's cervical
screening technologies includes the ThinPrep Pap test and imaging
system, Aptima HPV assays, the Tomcat pre-analytical processing
instrument, and the fully automated, sample-to-answer Panther
system.
"We are very pleased to partner with the National Health
Laboratory and support their cervical cancer screening programme,"
said Claus Egstrand, Hologic Group President, International. "Our
innovative assays and advanced automation platforms work together
seamlessly to accurately and efficiently detect cervical disease at
its earliest stage, when the likelihood of an improved patient
outcome is at its greatest. This partnership provides us with the
opportunity to make our world class portfolio of cervical screening
technologies more accessible to physicians and patients in
Luxembourg."
"Hologic has been a very responsive partner over the last year
as we transitioned to their cervical screening platform," said Dr.
Marc Fischer, Cytology Laboratory
Manager at the National Health Laboratory. "Our decision to convert
to Hologic's cervical health solutions was based on improved sample
quality with ThinPrep, greater workflow efficiencies and
scalability with the Panther system, and the flexibility to expand
our cytology capabilities to include HPV screening in the
future."
Luxembourg has an estimated
population of over 200,000 women ages 15 and older who are at risk
of developing cervical cancer. Under current Luxembourg guidelines, initial cervical
screening should take place at age 20 with follow-up screening
intervals of one to three years.
About Hologic Advanced Cervical Screening Solutions
Cervical cancer is one of the most common cancers among women in
the world, and HPV is responsible for more than 99% of all cervical
cancers. Hologic's ThinPrep Pap test is one of the most widely used
methods for cervical screening.
The Aptima HPV assay is a nucleic acid amplification test that
detects 14 high-risk strains of human papillomavirus (HPV) mRNA
associated with cervical cancer and precancerous lesions from the
E6/E7 oncogenes. The Aptima HPV assay can be used with ThinPrep
liquid cytology specimens, either before or after the sample has
been processed for cytology testing on a ThinPrep slide processor.
With this solution, Hologic enables co-testing and triage testing
with cytology and HPV from one sample to be executed efficiently
and in a high quality.
Hologic's automation platforms are designed to improve
productivity, enhance chain-of-custody procedures and deliver
reliable, reproducible results. Tomcat is a fully automated general
purpose instrument designed to ease the strain of pre-analytical
sample processing by eliminating the inefficient and error-prone
activities required to manually aliquot samples. The Panther system
is a scalable testing platform for virtually any size lab
environment. A fully automated, sample-to-answer instrument, the
Panther system eliminates the need for batch processing and
automates all aspects of nucleic acid amplification testing on a
single, integrated platform.
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Hologic, Aptima, Panther, ThinPrep, The Science of Sure, Tomcat
and associated logos are trademarks and/or registered trademarks of
Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-looking Statement Disclaimer
This press release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic's ThinPrep Pap test platform, Aptima HPV assays and
the Tomcat instrument and Panther system. There can be no assurance
the assays and systems will achieve the benefits described herein
and that such benefits will be replicated in any particular manner
with respect to an individual patient as the actual effect of the
use of the assays and systems can only be determined on a
case-by-case basis depending on the particular circumstances and
patient in question. Hologic expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to the
statements presented herein to reflect any change in the Company's
expectations or any change in events, conditions or circumstances
on which any such statements are based.
Contacts:
|
|
|
|
Marianne McMorrow
|
Carol Smith
|
Manager, Corporate Communications
|
Manager, Marketing Communications
|
+1 (781) 999 7723
|
+44 (0) 161 946 2220
|
marianne.mcmorrow@hologic.com
|
carol.smith@hologic.com
|